Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma
Artinyan A et al. – Neoadjuvant therapy has been used to improve survival in operable pancreatic cancer. The authors' objective was to compare long–term outcomes in patients receiving neoadjuvant versus adjuvant therapy for resectable pancreatic adenocarcinoma. This is the first population–based study to compare neoadjuvant versus adjuvant treatment strategies in resectable pancreatic cancer. Neoadjuvant therapy is associated with a lower rate of lymph node positivity and improved overall survival and should be considered an acceptable alternative to the surgery–first paradigm in operable pancreatic cancer.